Back to Journals » Neuropsychiatric Disease and Treatment » Cariprazine in schizophrenia
Neuropsychiatric Disease and Treatment
ISSN: 1178-2021
- View all (4246)
- Volume 20, 2024 (140)
- Volume 19, 2023 (249)
- Volume 18, 2022 (272)
- Volume 17, 2021 (351)
- Volume 16, 2020 (325)
- Volume 15, 2019 (353)
- Volume 14, 2018 (354)
- Volume 13, 2017 (333)
- Volume 12, 2016 (367)
- Volume 11, 2015 (340)
- Volume 10, 2014 (275)
- Volume 9, 2013 (223)
- Volume 8, 2012 (74)
- Volume 7, 2011 (87)
- Volume 6, 2010 (90)
- Volume 5, 2009 (65)
- Volume 4, 2008 (128)
- Volume 3, 2007 (105)
- Volume 2, 2006 (70)
- Volume 1, 2005 (45)
Journal Articles:
- Autism, the disorder without borders and geopolitical variations (7)
- Epileptic disorders: advances in the diagnostic and therapeutic strategies (3)
- Cognitive dysfunction in bipolar disorder: Bio-psycho-social perspective (1)
- Beneath the surface: genetic factors in schizophrenia (3)
- The effectiveness of non-pharmacological interventions for people with cognitive dysfunction (1)
- Stroke and neurorestoratology (1)
- Suicide Prevention and Intervention: Recent Evidence and Future Directions (4)
- Family and Peer Facilitated/Led Interventions for Severe Mental Health Problems (2)
- Therapeutic Response to Psychedelic Therapy – Who, What, Why & How? (3)
- Current Perspectives of Chronic Stress: from Neurobiology to Treatment (3)
- Issues and Solutions in Autism Spectrum Disorders (ASD) (9)
- Cariprazine in schizophrenia (5)
- The Caregiver Perspective on Pediatric ADHD (3)
- Volume 7 - Supplement 1 (5)
- Volume 6 - Supplement 1 (6)
Cariprazine in schizophrenia
Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D3 and D2 receptor partial agonist, with a preference for the D3 receptor. While clinical trials are mandatory to provide solid data about the efficacy and tolerability of pharmacological treatments, they may not be representative of the entire patient population, which comprises patients often excluded from clinical trials, showing complex clinical presentation and poor response to usual treatments. This Thematic Series thus provides real-world clinical cases that could help to improve the knowledge of actual effectiveness and tolerability of cariprazine in more difficult clinical scenarios.
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
Montes JM, Montes P, Hernández-Huerta D
Neuropsychiatric Disease and Treatment 2021, 17:291-296
Published Date: 3 February 2021
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
Müller HHO, Moeller S
Neuropsychiatric Disease and Treatment 2021, 17:1089-1093
Published Date: 15 April 2021
Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
Bajouco M, Mota D
Neuropsychiatric Disease and Treatment 2022, 18:1351-1362
Published Date: 5 July 2022
Cariprazine: Patients with Treatment-Resistant Schizophrenia
Aubel T
Neuropsychiatric Disease and Treatment 2021, 17:2327-2332
Published Date: 14 July 2021
Cariprazine in Three Special Different Areas: A Real-World Experience
Gesi C, Paletta S, Palazzo M C, Dell'Osso B, Mencacci C, Cerveri G
Neuropsychiatric Disease and Treatment 2021, 17:3581-3588
Published Date: 7 December 2021